Skip to main content

Advertisement

Table 2 Distribution of cytokines scores of the change from start of treatment to 16 weeks after the start of treatment by autoantibodies

From: Biologic predictors of clinical improvement in rituximab-treated refractory myositis

Change from baseline to 16 weeks later Anti-synthetase TIF SRP MJ MI-2 Other AutoAb No AutoAb Undefined P value
(N = 23) (N = 15) (N = 18) (N = 15) (N = 13) (N = 18) (N = 29) (N = 9)
IFNCKa −6.7 7.0 −0.3 1.2 −6.1 −0.7 2.0 −8.7 <.001
(−80.8, 15.5) (−6.7, 35.3) (−21.9, 28.8) (−41.2, 23.6) (−82.0, 31.6) (−37.7, 18.4) (−30.6, 15.9) (−25.8, 10.5)
TH1 −3.4 −0.9 0.4 0.8 −2.6 −3.6 −0.3 −2.4 0.039
(−44.9, 34.5) (−4.9, 34.9) (−44.0, 63.3) (−20.7, 32.2) (−27.8, 3.6) (−20.7, 17.7) (−59.8, 41.8) (−6.0, 60.3)
TH2 −1.4 0.6 1.1 2.4 0.2 −0.3 1.4 1.3 0.11
(−9.5, 6.1) (−17.5, 5.8) (−7.5, 41.1) (−7.0, 41.4) (−5.7, 8.8) (−51.9, 19.5) (−69.3, 25.5) (−5.1, 23.8)
TH17 −0.0 3.3 3.9 0.0 2.1 0.6 3.0 −1.0 0.50
(−22.4, 26.8) (−20.2, 26.7) (−15.8, 45.7) (−25.3, 43.2) (−18.8, 39.1) (−22.0, 24.5) (−20.4, 43.0) (−13.3, 13.8)
Innate 2.0 3.7 2.7 3.6 −1.0 1.4 7.6 2.1 0.029
(−21.7, 14.9) (−7.8, 24.0) (−6.6, 34.5) (−20.3, 21.6) (−24.3, 8.3) (−14.5, 23.2) (−16.5, 22.1) (−20.1, 14.0)
Regulatory −5.8 −1.9 −0.7 −0.2 −3.4 −7.2 −1.4 −2.9 0.028
(−50.3, 17.1) (−15.4, 15.1) (−15.4, 55.3) (−16.6, 25.0) (−32.2, 9.1) (−50.0, 24.9) (−47.0, 45.7) (−11.7, 12.7)
  1. aIFNCK IFN chemokine score